中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 12
Dec.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(12): 2809-2816

Predictors of HBsAg clearance in HBeAg-negative chronic hepatitis B patients treated with pegylated interferon α-2b and the construction of a nomogram model

DOI: 10.3969/j.issn.1001-5256.2023.12.010

  • Department of Infectious Diseases，The Affiliated Hospital of Xuzhou Medical University，Xuzhou，Jiangsu 221002，China

Research funding:

National Science and Technology Key Project (2018ZX10302206-003-010);

Natural Science Research in Higher Education Institutions in Jiangsu Province (KY13012001)

More Information
  • Corresponding author: LI Chunyang， 13775989791@126.com （ORCID： 0009-0006-9200-6208）
  • Received Date: 2023-03-13
  • Accepted Date: 2023-04-18
  • Published Date: 2023-12-12
    Abstract
  •   Objective  To establish an early predictive model using serological markers based on LASSO regression for predicting the possibility of HBsAg clearance in HBeAg-negative chronic hepatitis B （CHB） patients treated with pegylated interferon α-2b （PEG-IFNα-2b）， and to investigate the diagnostic value of the model.  Methods  A total of 136 HBeAg-negative CHB patients who received PEG-IFNα-2b treatment in the Affiliated Hospital of Xuzhou Medical University from April 2020 to October 2021 were enrolled， among whom 47 received PEG-IFNα-2b for the first time （previously untreated） and 89 received PEG-IFNα-2b after 48 weeks of treatment with nucleos（t）ide analogues （treatment-experienced）. The patients were randomly assigned to a training set with 95 patients and a validation set with 41 patients at a ratio of 7∶3， and related data were collected for both groups， including virological markers， routine blood test results， and liver function at baseline and week 12 of treatment. According to HBsAg status at week 48 of treatment， the patients were divided into seroconversion group with 38 patients and non-seroconversion group with 98 patients. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Wilcoxon rank-sum test was used for comparison of non-normally distributed continuous data between two groups； the chi-square test was used for comparison of categorical variables between two groups. The LASSO regression analysis and univariate and multivariate logistic regression analyses were used to establish a nomogram model； the receiver operating characteristic （ROC） curve was used to assess its predictive ability， and the area under the ROC curve （AUC） was used for comparison of predictive value.  Results  In the training set， 95 HBeAg-negative CHB patients were treated with PEG-IFNα-2b for 48 weeks， among whom there were 27 patients in the seroconversion group and 68 in the non-seroconversion group. The univariate Logistic regression analysis， with P<0.2 as the criterion for screening， showed that 9 indicators were included in the LASSO regression analysis， i.e.， sex， baseline HBV DNA level， the reduction in HBV DNA in 0 — 12 weeks， baseline HBsAg level， the reduction in HBsAg in 0 — 12 weeks， baseline aspartate aminotransferase （AST） level， the reduction in AST in 0 — 12 weeks， baseline alanine aminotransferase （ALT） level， and the reduction in ALT in 0 — 12 weeks. The LASSO regression analysis showed that sex， baseline HBsAg level， the reduction in HBsAg in 0 — 12 weeks， and the reduction in ALT in 0 — 12 weeks were non-zero variables and were included in the multivariate Logistic regression analysis. The multivariate Logistic regression analysis obtained 4 independent predictive factors， i.e.， sex （odds ratio ［OR］=5.38， 95% confidence interval ［CI］： 1.11 — 34.21， P=0.049）， baseline HBsAg level （OR=0.12， 95%CI： 0.04 — 0.26， P<0.001）， the reduction in HBsAg in 0 — 12 weeks （OR=5.54， 95%CI： 1.97 — 19.18， P=0.003）， and the reduction in ALT in 0 — 12 weeks （OR=0.99， 95%CI： 0.97 — 1.00， P=0.039）. A nomogram model was established based on the results of the multivariate Logistic regression analysis， and the ROC curve was used to assess the predictive value of this nomogram model. This nomogram model had an AUC of 0.934 （95%CI： 0.886 — 0.981） in the training set and an AUC of 0.921 （95%CI： 0.838 — 1.000） in the validation set. In addition， the results of calibration curve and decision curve analyses showed that the model had good consistency and accuracy.  Conclusion  Based on general information and serological markers， the LASSO regression analysis is used to establish a nomogram model using sex， baseline HBsAg level， the reduction in HBsAg in 0 — 12 weeks， and the reduction in ALT in 0 — 12 weeks， and this model can be used to predict the probability of achieving HBsAg clearance in HBeAg-negative CHB patients treated with PEG-IFNα-2b， which provides important reference and theoretical support for the clinical treatment of patients.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    JENG WJ, PAPATHEODORIDIS GV, LOK ASF. Hepatitis B[J]. Lancet, 2023, 401( 10381): 1039- 1052. DOI: 10.1016/S0140-6736(22)01468-4.
    [2]
    ASPINALL EJ, HAWKINS G, FRASER A, et al. Hepatitis B prevention, diagnosis, treatment and care: A review[J]. Occup Med, 2011, 61( 8): 531- 540. DOI: 10.1093/occmed/kqr136.
    [3]
    Chinese Society of Infectious Disease, Chinese Society of Hepatology, Chinese Medical Association. The expert consensus on functional cure of chronic hepatitis B[J]. J Clin Hepatol, 2022, 30( 12): 1309- 1331. DOI: 10.3760/cma.j.cn501113-20221204-00607.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 临床肝胆病杂志, 2022, 30( 12): 1309- 1331. DOI: 10.3760/cma.j.cn501113-20221204-00607.
    [4]
    NGUYEN MH, WONG G, GANE E, et al. Hepatitis B virus: Advances in prevention, diagnosis, and therapy[J]. Clin Microbiol Rev, 2020, 33( 2): e00046- e00019. DOI: 10.1128/CMR.00046-19.
    [5]
    TSENG TC, KAO JH, CHEN DS. Peginterferon α in the treatment of chronic hepatitis B[J]. Expert Opin Biol Ther, 2014, 14( 7): 995- 1006. DOI: 10.1517/14712598.2014.907784.
    [6]
    MIMURA S, FUJITA K, TAKUMA K, et al. Effect of pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B during and 48 weeks after off-treatment follow-up: The limitation of pre-treatment HBsAg load for the seroclearance of HBsAg[J]. Intern Emerg Med, 2021, 16( 6): 1559- 1565. DOI: 10.1007/s11739-020-02622-7.
    [7]
    KWON H, LOK AS. Hepatitis B therapy[J]. Nat Rev Gastroenterol Hepatol, 2011, 8( 5): 275- 284. DOI: 10.1038/nrgastro.2011.33.
    [8]
    ALHAMZAWI R, ALI HTM. The Bayesian adaptive lasso regression[J]. Math Biosci, 2018, 303: 75- 82. DOI: 10.1016/j.mbs.2018.06.004.
    [9]
    VLACHOGIANNAKOS J, PAPATHEODORIDIS GV. HBeAg-negative chronic hepatitis B: Why do I treat my patients with pegylated interferon-alfa?[J]. Liver Int, 2014, 34( Suppl 1): 127- 132. DOI: 10.1111/liv.12404.
    [10]
    SHEPHERD J, JONES J, TAKEDA A, et al. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: A systematic review and economic evaluation[J]. Health Technol Assess, 2006, 10( 28): ⅲ-ⅳ, ⅺ-xiv, 1- 183. DOI: 10.3310/hta10280.
    [11]
    YE JY, CHEN JL. Interferon and hepatitis B: Current and future perspectives[J]. Front Immunol, 2021, 12: 733364. DOI: 10.3389/fimmu.2021.733364.
    [12]
    QIAN JD, ZHAO H, WANG GQ. Current status of the treatment of chronic hepatitis B-related liver fibrosis/cirrhosis[J]. J Clin Hepatol, 2021, 37( 12): 2909- 2913. DOI: 10.3969/j.issn.1001-5256.2021.12.036.

    钱建丹, 赵鸿, 王贵强. 慢性乙型肝炎肝纤维化/肝硬化的治疗现状[J]. 临床肝胆病杂志, 2021, 37( 12): 2909- 2913. DOI: 10.3969/j.issn.1001-5256.2021.12.036.
    [13]
    LI H, XU WT, DENG BC, et al. Progress in the functional treatment of chronic hepatitis B with nucleos(t)ide analogues and pegylated interferon[J]. Clin J Med Offic, 2022, 50( 9): 890- 893. DOI: 10.16680/j.1671-3826.2022.09.04.

    李卉, 许文涛, 邓宝成, 等. 核苷(酸)类似物联合聚乙二醇干扰素功能性治愈慢性乙型肝炎研究进展[J]. 临床军医杂志, 2022, 50( 9): 890- 893. DOI: 10.16680/j.1671-3826.2022.09.04.
    [14]
    ZHANG WH, ZHANG DZ, DOU XG, et al. Consensus on pegylated interferon alpha in treatment of chronic hepatitis B[J]. Chin J Hepatol, 2017, 25( 9): 678- 686. DOI: 10.3760/cma.j.issn.1007-3418.2017.09.007.

    张文宏, 张大志, 窦晓光, 等. 聚乙二醇干扰素α治疗慢性乙型肝炎专家共识[J]. 中华肝脏病杂志, 2017, 25( 9): 678- 686. DOI: 10.3760/cma.j.issn.1007-3418.2017.09.007.
    [15]
    GUO YF, ZHANG JM. Influencing factors for the functional cure of chronic hepatitis B and related mechanism[J]. J Clin Hepatol, 2022, 38( 8): 1721- 1725. DOI: 10.3969/j.issn.1001-5256.2022.08.004.

    郭艺飞, 张继明. 影响慢性乙型肝炎功能性治愈的因素及其机制[J]. 临床肝胆病杂志, 2022, 38( 8): 1721- 1725. DOI: 10.3969/j.issn.1001-5256.2022.08.004.
    [16]
    OMATA M, CHENG AL, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update[J]. Hepatol Int, 2017, 11( 4): 317- 370. DOI: 10.1007/s12072-017-9799-9.
    [17]
    European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67( 2): 370- 398. DOI: 10.1016/j.jhep.2017.03.021.
    [18]
    LIANG TJ, BLOCK TM, MCMAHON BJ, et al. Present and future therapies of hepatitis B: From discovery to cure[J]. Hepatology, 2015, 62( 6): 1893- 1908. DOI: 10.1002/hep.28025.
    [19]
    CHEN XF, ZHANG DJ, LUO XD, et al. Current status of the treatment of chronic hepatitis B[J]. J Clin Hepatol, 2021, 37( 5): 1011- 1015. DOI: 10.3969/j.issn.1001-5256.2021.05.004.

    陈学福, 张东敬, 罗晓丹, 等. 慢性乙型肝炎的治疗现状[J]. 临床肝胆病杂志, 2021, 37( 5): 1011- 1015. DOI: 10.3969/j.issn.1001-5256.2021.05.004.
    [20]
    XIE F, XIONG X, YAO CX, et al. Clinical efficacy and influencing factors of pegylated interferon alfa-2b and nucleos(t)ide analogue in chronic hepatitis B patients with low level of hepatitis B virus surface antigen[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2022, 16( 4): 247- 253. DOI: 10.3877/cma.j.issn.1674-1358.2022.04.005.

    谢芳, 熊熙, 姚传霞, 等. 聚乙二醇化干扰素α-2b联合核苷(酸)类似物治疗低水平乙型肝炎病毒表面抗原慢性乙型肝炎患者的临床疗效及影响因素[J/CD]. 中华实验和临床感染病杂志(电子版), 2022, 16( 4): 247- 253. DOI: 10.3877/cma.j.issn.1674-1358.2022.04.005.
    [21]
    CHU JH, HUANG Y, XIE DY, et al. Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients[J]. J Viral Hepat, 2022, 29( 9): 765- 776. DOI: 10.1111/jvh.13722.
    [22]
    LI MH, ZHANG L, LU Y, et al. Early serum HBsAg kinetics as predictor of HBsAg loss in patients with HBeAg-negative chronic hepatitis B after treatment with pegylated interferonα-2a[J]. Virol Sin, 2021, 36( 2): 311- 320. DOI: 10.1007/s12250-020-00290-7.
    [23]
    HU P, SHANG J, ZHANG WH, et al. HBsAg loss with peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: New switch study[J]. J Clin Transl Hepatol, 2018, 6( 1): 25- 34. DOI: 10.14218/JCTH.2017.00072.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(6)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (412) PDF downloads(87) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return